MNPR

Monopar Therapeutics (MNPR)

About Monopar Therapeutics (MNPR)

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Details

Daily high

$5.70

Daily low

$5.11

Price at open

$5.56

52 Week High

$8.65

52 Week Low

$1.37

Market cap

18.2M

Dividend yield

0.00%

Volume

159,578

Avg. volume

411,306

P/E ratio

-2.24

Monopar Therapeutics News